2022
DOI: 10.1021/acschembio.1c00824
|View full text |Cite
|
Sign up to set email alerts
|

Discovery of Non-Cysteine-Targeting Covalent Inhibitors by Activity-Based Proteomic Screening with a Cysteine-Reactive Probe

Abstract: Covalent inhibitors of enzymes are increasingly appreciated as pharmaceutical seeds, yet discovering non-cysteinetargeting inhibitors remains challenging. Herein, we report an intriguing experience during our activity-based proteomic screening of 1601 reactive small molecules, in which we monitored the ability of library molecules to compete with a cysteine-reactive iodoacetamide probe. One epoxide molecule, F8, exhibited unexpected enhancement of the probe reactivity for glyceraldehyde-3phosphate dehydrogenas… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
16
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 11 publications
(16 citation statements)
references
References 52 publications
0
16
0
Order By: Relevance
“…GAPDH is an enzyme that canonically uses a pK-perturbed active-site cysteine to bind and reduce nicotinamide adenine dinucleotide (NAD) in glycolysis but consistent with its high abundance also engages in extensive moonlighting activities . Due to its high abundance and pK-perturbed active-site cysteines, GAPDH is a frequent conjugation target of electrophilic molecules. , GAPDH is found in Parkinson’s disease (PD)-associated aggregates, and its aggregation is promoted by electrophilic conjugation . Given its abundance and fold change in the DNAJB8 co-IP recovery, it is likely that GAPDH is the feature observed by silver stain at 37 kDa (Figure S4).…”
Section: Resultsmentioning
confidence: 99%
“…GAPDH is an enzyme that canonically uses a pK-perturbed active-site cysteine to bind and reduce nicotinamide adenine dinucleotide (NAD) in glycolysis but consistent with its high abundance also engages in extensive moonlighting activities . Due to its high abundance and pK-perturbed active-site cysteines, GAPDH is a frequent conjugation target of electrophilic molecules. , GAPDH is found in Parkinson’s disease (PD)-associated aggregates, and its aggregation is promoted by electrophilic conjugation . Given its abundance and fold change in the DNAJB8 co-IP recovery, it is likely that GAPDH is the feature observed by silver stain at 37 kDa (Figure S4).…”
Section: Resultsmentioning
confidence: 99%
“…The protein hits ALDH2, GSTO1, and GAPDH were further validated by pull-down and WB using the corresponding antibodies (Figure B). Notably, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a druggable target related to various diseases, , corresponds to the specific labeling band at low probe concentrations in different cancer cell lines (Figure E, right gel). Immunofluorescence experiments showed that the probe is co-localized well with GAPDH at the low probe concentration of 1 μM (Figure I).…”
Section: Resultsmentioning
confidence: 99%
“…GAPDH is an enzyme that canonically uses a susceptible active-site cysteine to bind and reduce nicotinamide adenine dinucleotide (NAD) in glycolysis 72 , but consistent with its high abundance also engages in extensive moonlighting activities 73 . Due to its high abundance and pK-perturbed active site cysteines, GAPDH is a frequent conjugation target of electrophilic molecules 74,75 .…”
Section: Small Structural Differences Have Been Shown To Have Large E...mentioning
confidence: 99%